Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | SLC16A3 | O15427 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.57 |
| ▸ | FABP4 | P15090 | 4/20 | 0.52 |
| ▸ | WDR5 | P61964 | 1/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561271 | 0.92 | SLC16A3 (0.74) | TSHRSLC16A3ALDH1A1HTTPFKFB3 | |
| SCHEMBL3559856 | 0.91 | TSHR (0.85) | TSHRSLC16A3ALDH1A1HTTPFKFB3 | |
| SCHEMBL3559548 | 0.89 | SLC16A3 (0.73) | TSHRSLC16A3ALDH1A1HTTPFKFB3 | |
| SCHEMBL3563292 | 0.85 | PTK2B (0.58) | TSHRSLC16A3ALDH1A1FABP4NR1I2 | |
| SCHEMBL3563988 | 0.84 | SLC16A3 (0.67) | TSHRSLC16A3ALDH1A1HTTPFKFB3 | |
| SCHEMBL3557477 | 0.84 | SLC16A3 (0.50) | TSHRSLC16A3FABP4 | |
| SCHEMBL3562220 | 0.84 | EDNRA (0.52) | TSHRSLC16A3FABP4HDAC1 | |
| SCHEMBL3555628 | 0.83 | HTR6 (0.65) | SLC16A3PFKFB3HDAC1 | |
| SCHEMBL15762086 | 0.83 | TSHR (1.00) | TSHRSLC16A3ALDH1A1HTTPFKFB3 | |
| SCHEMBL3562430 | 0.82 | IDH1 (0.53) | TSHRSLC16A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | TSHR 3483/4885SLC16A3 425/4885ALDH1A1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.